We are pleased with the Fast Track designation, and believe that the FDA supports our research efforts in patients associated with A1AD
AGTC's treatment for A1AD utilizes its Adeno-Associated Virus technology to deliver the normal human gene to patients so their body can produce the missing protein.
Extensive pre-clinical work has been completed on the Company's treatment for A1AD and AGTC is currently raising a Series B venture investment of $12 million in order to fund Human Clinical Trials and scale-up its production process to support market launch.
AGTC is currently raising a Series B venture investment of $12 million in order to fund Phase II Human Clinical Trials for its A1AD
product and to scale-up its production process to support market launch.
AAV vectors treating A1AD
and Pompe's are two of several novel gene therapy treatments, for both human and veterinary uses, that AGTC is developing.
The 50-year-old pop superstar - who has previously been photographed looking frail in a wheelchair - is said to be battling inherited condition A1AD
(alpha-1 antitrypsin deficiency) which leaves sufferers without a protein needed to protect the lungs.